Another interventional study concern 211 prostate cancer patients at newly diagnosed metastatic stage (stage IV) (ClinicalTrials.gov Identifier: NCT01120236), were as a secondary outcome was measured correlation level between miR-141, miR-210, miR-200b and miR-375 as well as PSA level and circulating tumor cells (CTC). The gene discussed is PROS1; the disease is prostate carcinoma.